PRESENTATION TITLE:
H. pylori

PRESENTER(S):
Stephanie Hansel, M.D.

LEARNING OBJECTIVES
Upon completion of this activity, participants should be able to:

• Explain the clinical significance of Helicobacter pylori (H. pylori), including its role in the development of gastric cancer, and mucosa-associated lymphoid tissue (MALT) lymphoma.
• Outline the current recommendations for testing H. pylori, including identifying patient populations who would benefit from testing.
• Evaluate the current recommended treatment regimens considering resistance patterns, including the shift from clarithromycin-based triple therapy to bismuth quadruple therapy.
• Articulate the importance of testing for the eradication of H. pylori following treatment, including understanding the recommended timing and methods for post-treatment testing.
• Identify the treatment regimens for H. pylori salvage therapy, including the selection of appropriate second-line or third-line treatments, and the consideration of antibiotic resistance patterns to ensure successful eradication of the infection.

ATTENDANCE / CREDIT
Text the session code (provided only at the session) to 507-200-3010 within 48 hours of the live presentation to record attendance. All learners are encouraged to text attendance regardless of credit needs. This number is only used for receiving text messages related to tracking attendance. Additional tasks to obtain credit may be required based on the specific activity requirements and will be announced accordingly. Swiping your badge will not provide credit; that process is only applicable to meet GME requirements for Residents & Fellows.

TRANSCRIPT
Any credit or attendance awarded from this session will appear on your Transcript.

For disclosure information regarding Mayo Clinic School of Continuous Professional Development accreditation review committee member(s) and staff, please go here to review disclosures.